[{"id":"02e7dd18-d658-4ef3-b1a4-9d2da53c05e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05846659","created_at":"2023-05-06T14:04:14.307Z","updated_at":"2024-07-02T16:34:36.888Z","phase":"Phase 2","brief_title":"Study of PULSAR-ICI +/- IMSA101 in Patients With Oligoprogressive Solid Tumor Malignancies","source_id_and_acronym":"NCT05846659","lead_sponsor":"ImmuneSensor Therapeutics Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • IMSA101"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2023","start_date":" 07/07/2023","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-06-10"},{"id":"0a8b544d-5385-4b08-8266-87f1c34ba6c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04020185","created_at":"2021-01-18T19:44:10.860Z","updated_at":"2024-07-02T16:35:33.960Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study of IMSA101 in Refractory Malignancies","source_id_and_acronym":"NCT04020185","lead_sponsor":"ImmuneSensor Therapeutics Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" HR negative","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IMSA101"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/23/2019","start_date":" 09/23/2019","primary_txt":" Primary completion: 09/15/2023","primary_completion_date":" 09/15/2023","study_txt":" Completion: 09/15/2023","study_completion_date":" 09/15/2023","last_update_posted":"2023-10-11"}]